Results 1 to 10 of about 924 (199)

Acinetobacter baumannii Resistance to Sulbactam/Durlobactam: A Systematic Review [PDF]

Antibiotics, 2022
Infections caused by carbapenem-resistant Acinetobacter baumannii (CRAB) have limited therapeutic options. Sulbactam-durlobactam is a combination of two βlactamase inhibitors with activity against CRAB under phase 3 clinical investigation. We performed a
Luigi Principe, Stefano Di Bella, Jacopo Conti, Mariagrazia Perilli, Alessandra Piccirilli, Cristina Mussini, Giuliana Decorti   +6 more
doaj   +7 more sources

Durlobactam, a New Diazabicyclooctane β-Lactamase Inhibitor for the Treatment of Acinetobacter Infections in Combination With Sulbactam [PDF]

Frontiers in Microbiology, 2021
Durlobactam is a new member of the diazabicyclooctane class of β-lactamase inhibitors with broad spectrum activity against Ambler class A, C, and D serine β-lactamases.
Adam B Shapiro, Samir H Moussa, Sarah M McLeod   +2 more
exaly   +5 more sources

Sulbactam-durlobactam combination therapy for carbapenem-resistant <i>Acinetobacter baumannii</i> sepsis with cutaneous involvement in an infant with acute monocytic leukemia: A case report. [PDF]

Front Pharmacol
Carbapenem-resistant Acinetobacter baumannii (CRAb) causes severe infections and poses significant treatment challenges. Sulbactam-durlobactam (SUL-DUR) is a novel antibiotic, but its use in children and infants has not been reported.
Fu C, Tang X, Guo X, Huang L, Gao J, Yang R.   +5 more
europepmc   +5 more sources

Sulbactam-durlobactam improves cephalosporin and carbapenem susceptibility and time-kill effect against <i>Mycobacterium abscessus</i>. [PDF]

Microbiol Spectr
Despite the long therapy duration, the treatment outcomes for Mycobacterium abscessus lung disease (MAB-LD) are very poor. β-Lactams are among the recommended drugs for the treatment of MAB-LD; however, they are prone to hydrolysis by MAB β-lactamase ...
Shrivastava A, Boorgula GD, Singh S, Stiles D, McShane PJ, Devine M, Devine M, Gumbo T, Srivastava S.   +8 more
europepmc   +4 more sources

Cefiderocol and Sulbactam-Durlobactam against Carbapenem-Resistant Acinetobacter baumannii

Antibiotics, 2023
Infections caused by carbapenem-resistant Acinetobacter baumannii (CRAB) remain a clinical challenge due to limited treatment options. Recently, cefiderocol, a novel siderophore cephalosporin, and sulbactam-durlobactam, a bactericidal β-lactam–β ...
Arta Karruli, Antonella Migliaccio, Spyros Pournaras, Emanuele Durante-Mangoni, Raffaele Zarrilli   +4 more
doaj   +5 more sources

Durlobactam in the Treatment of Multidrug-Resistant Acinetobacter baumannii Infections: A Systematic Review

Journal of Clinical Medicine, 2022
A. baumannii is a frequent cause of difficult-to-treat healthcare-associated infections. The use of a novel beta-lactamase inhibitor, durlobactam, has been proposed against multidrug-resistant A. baumannii. A systematic review of studies assessing the efficacy and safety of durlobactam in the treatment of multidrug-resistant A. baumannii infections was
Guido Granata, Francesco Schiavone, Nicola Petrosillo   +2 more
exaly   +3 more sources

Resistance of <i>Acinetobacter baumannii</i> Complex Clinical Isolates to Sulbactam-Durlobactam: A Systematic Review of Data from In Vitro Studies. [PDF]

Pathogens
Introduction: Due to the limited therapeutic options for patients with Acinetobacter baumannii complex infections, a new combination antimicrobial agent, sulbactam–durlobactam, has been developed.
Falagas ME, Romanos LT, Ragias D, Filippou C.   +3 more
europepmc   +2 more sources

Loss-of-Function Mutations in the Penicillin-Binding Protein PonA1 Confer Agar-Dependent Resistance to Durlobactam in <i>Mycobacterium abscessus</i>. [PDF]

Antibiotics (Basel)
Background: Infections caused by the multidrug-resistant pathogen Mycobacterium abscessus (Mab) are notoriously difficult to treat. The novel β-lactamase inhibitor durlobactam, in combination with β-lactams, shows potent bactericidal activity against Mab,
Negatu DA, Aragaw WW, Xie M, Dartois V, Dick T.   +4 more
europepmc   +2 more sources

Activity of Sulbactam-Durlobactam and Comparators Against a National Collection of Carbapenem-Resistant Acinetobacter baumannii Isolates From Greece

Frontiers in Cellular and Infection Microbiology, 2022
BackgroundAcinetobacter baumannii is a leading cause of healthcare-associated infections worldwide, due to both its persistence in the hospital setting and ability to acquire high levels of antibiotic resistance. Carbapenem-resistant A.
Maria Siopi, Spyros Pournaras
exaly   +3 more sources

Sulbactam-Durlobactam for Carbapenem-Resistant <i>Acinetobacter baumannii-calcoaceticus</i> Complex. [PDF]

Pathogens
Carbapenem-resistant Acinetobacter baumannii infections pose a significant challenge due to their severity and the poor prognoses they often result in, particularly in cases where there are risk factors present. The United States (US) Centers for Disease
Nappi F.
europepmc   +2 more sources